Final 24-month analysis of a phase 3 trial in 477 adults with IgA nephropathy: iptacopan slowed annualised eGFR decline vs placebo (-3.10 vs -6.12; difference 3.02); kidney-failure events 21.4% vs 33.5%; serious infections 6.7% vs 2.1%.
RCTn = 477
Barratt et al. Iptacopan in IgA Nephropathy - Final 24-Month Data